Aravax is a clinical stage biotechnology company developing a novel peptide-based immunotherapy, PVX108, for the treatment of peanut allergy.
Aravax
Developing a safe, convenient, disease-modifying treatment for everyone with peanut allergy.
Date Founded
-
Founders / Management
Dr Pascal Hickey - CEO
HQ
Melbourne, VIC
Location(s)
Australia
Website
-
LinkedIn
-
Twitter
-
Facebook
-
Instagram
-
Contact
-